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Summary: Purpose: To evaluate a canine intestinal access- 
port model to study colonic absorption of drugs. The antiepi- 
leptic drugs phenytoin and gabapentin were chosen to study 
absorption of a lipophilic and hydrophilic compound, respec- 
tively. 
Methods: Drug plasma level-time plots were generated sub- 
sequent to small intestinal and colonic drug administration of 
both drugs. The poorly water-soluble phenytoin was adminis- 
tered in two doses to evaluate the impact of dissolution rate 
limits on colonic absorption. Maximal plasma concentration 
(Cmm) and area under the plasma level-time curve (AUC) were 
used to assess the relative contribution of colonic absorption to 
plasma levels. 
Results: Whereas colonic gabapentin AUC and C, were 
only 0.25 and 0.15 of those seen after small intestinal admin- 
istration, colonic phenytoin AUC and C, were one half and 
equivalent to, respectively, those observed for small intestinal 
administration. Furthermore, colonic administration of a higher 
phenytoin dose showed secondary maxima and continued in- 
creases in drug plasma levels with time. 
Conclusions: Colonic gabapentin absorption is poor com- 
pared with upper intestinal absorption, consistent with mem- 
brane transport rate limits to the absorption of this hydrophilic 
AED. Peak phenytoin plasma levels from colonic and small 
intestinal administration are comparable, indicating membrane 
transport does not limit absorption of this lipophilic agent. Con- 
tinued plasma-level increases from higher phenytoin doses are 
consistent with dissolution-rate control of drug absorption in 
the colon. We suggest that colonic absorption provides a 
greater potential for toxicity from phenytoin overdose as a 
function of continued drug dissolution than for gabapentin 
overdose. Key Words: Gabapentin-Phenytoin-Toxicity- 
Colonic absorption. 
Massive overdose cases have been reported (1,2) for 
the antiepileptic agents (AEDs) carbamazepine and phe- 
nytoin. Both of these agents are poorly water soluble 
(3,4), and their intestinal absorption is dissolution-rate 
controlled at typical oral doses. The case reports for car- 
bamazepine overdose (1) suggested that the presence of 
insoluble drug coagulum in the gastrointestinal tract may 
have been responsible for the maintenance of toxic 
plasma levels of carbamazepine and its metabolites over 
a 3-day period. In the case of the phenytoin overdose (2) ,  
a zero-order absorption process was observed to main- 
tain toxic plasma levels of the drug for a 12-day period. 
This zero-order absorption process is consistent with 
continued dissolution of undissolved phenytoin control- 
ling drug absorption at a constant rate fixed by aqueous 
solubility. 
In each of these cases, patients were reported to be 
comatose, and adequate time for undissolved drug to 
reach the lower bowel had been achieved. Thus contin- 
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ued dissolution with subsequent absorption of drug from 
the large intestine could result in sustaining plasma lev- 
els in the toxic range. As permeation of these lipophilic 
molecules across intestinal membranes is not rate limit- 
ing to absorption, continued absorption provided by dis- 
solution in the lower intestine is ensured. 
A number of oral-delivery systems have been de- 
signed for site-specific release of drug in the large intes- 
tine (5). We have used a long-term canine colonic- 
absorption model to study the potential for oral delivery 
of peptide drugs subject to degradation by proteolytic 
enzymes in the upper gastrointestinal tract (6).  Upper and 
lower intestinal access ports permit delivery of drug di- 
rectly into the small intestine and colon so that site- 
specific absorption can be studied uncoupled from dos- 
age-form release. Drug plasma level pharmacokinetics 
are assessed to permit a comparison of drug absorption 
from small intestinal and colonic administration. In the 
initial development of this animal model to study peptide 
absorption, the colonic absorption of lipophilic and hy- 
drophilic AEDs, phenytoin and gabapentin, respectively, 
were used to test the access-port system in a single dog. 
Although there was no intent systematically to evaluate 
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the absorption of these agents in this model, the results 
with these test compounds may be of clinical relevance. 
Phenytoin and gabapentin are cleared more rapidly in 
dogs than in humans. Phenytoin’s short elimination half- 
life in dogs results from a high capacity metahydox- 
ylation pathway in the liver (7). Gabapentin is N -  
methylated in dogs, whereas it is not metabolized in 
other species (8). Elimination half-life for both drugs is 
2-4 h in dogs (7,8), which is in the range of intestinal 
residence time. This dictates that changes in intestinal 
absorption will influence substantial control of drug 
plasma levels from oral and small intestinal dosing in 
dogs. Lengthy dissolution times for high doses of phe- 
nytoin in the colon will control absorption rate and in 
turn affect drug plasma-level kinetics. 
METHODS 
Vascular access ports (Access Technologies, Skokie, 
IL, U.S.A.) were surgically implanted to empty into the 
small intestine (40 cm distal to the pylorus) and colon 
(10 cm distal to the ileocecal junction) with external 
access from a syringe port in the animal’s back. Phenyt- 
oin was administered as Parke Davis Dilantin Suspen- 
sion, 25 mg/ml, at doses of 300 mg/12 ml in the small 
intestine and colon and 600 mg/24 ml in the colon. Gaba- 
pentin (also provided by Warner Lambert/Parke Davis) 
was administered as a 200 mg/lO ml dose in solution in 
normal saline. Access-port tubing was flushed with nor- 
mal saline to ensure complete administration of the drug 
dose. Phenytoin administration was carried out initially 
with a washout period of 2 1  week between treatments. 
The 600-mg colonic dose was the last of these three 
studies. Gabapentin administration was carried out sev- 
eral months later with a washout period of 2 1  week 
between treatments. 
High-performance liquid chromatography (HPLC) 
plasma assays for gabapentin (8) and phenytoin (9) were 
used as previously reported. Phenytoin plasma samples 
were extracted with ethyl ether, dried under nitrogen, and 
reconstituted with mobile phase after addition of methyl 
phenylhydantoin as an internal standard. The five stan- 
dard concentrations used covered experimental plasma- 
level concentration ranges, and between-day precisions 
were between 3.2 and 7.8%. The minimal level of de- 
tection for phenytoin was 0.025 mg/ml. Gabapentin 
plasma samples were mixed with equal volumes of 5% 
trintrobenzene sulfonic acid and 6N hydrochloric acid, 
half saturated with sodium chloride, extracted with cy- 
clohexane, evaporated to dryness, and reconstituted with 
a 10% aqueous ethanol mobile phase after addition of 
cyclopentane acetic acid monohydrochloride as an inter- 
nal standard. Five standard concentrations covered ex- 
perimental plasma-level concentration ranges, and be- 
tween-day precisions were between 0.8 and 6%. The 
minimum level of gabapentin detection also was 0.025 
mg/ml. The HPLC system consisted of a Spectroflow 
773 absorbance detector, a Waters 501 HPLC pump, and 
a Waters 710B WISP autoinjector. Samples were in- 
jected onto a LiChrosorb RP-18 column at a flow rate of 
1.2 ml/min and analyzed at an absorbance of 228 nm for 
phenytoin and at a flow rate of 0.9 ml/min and absor- 
bance of 335 nm for gabapentin. 
RESULTS 
Drug plasma levels and pharmacokinetic parameters 
(C,, peak plasma levels, and AUC, area under the 
plasma level-time curve) from oral, upper intestinal, and 
colonic administration of 200-mg gabapentin are shown 
in Fig. 1 and Table 1, respectively. Comparison of the 
blood-level data from oral and jejunal administration of 
gabapentin indicates that there is substantial absorption 
from the duodenum and upper jejunum. Most important, 
gabapentin plasma levels from colonic administration are 
substantially lower than those obtained from oral and 
upper intestinal administration (Fig. 1 and Table 1). 
Drug-plasma levels and pharmacokinetic parameters 
from upper intestinal administration of 300 mg and co- 
lonic administration of 300 mg and 600 mg of phenytoin 
are shown in Fig. 2 and Table 1, respectively. Peak 
plasma levels from colonic administration are in a range 
similar to those obtained from small intestinal adminis- 
tration of 300 mg phenytoin. Oral administration of phe- 
nytoin was not carried out in this study. However, a 
comparison of plasma levels from oral and intestinal 
phenytoin administration with a much higher volume 
load in a previous fasted- versus fed-state study (10) 
yielded comparable peak drug-plasma levels from the 
two administration sites in the fasted state. 
Phenytoin plasma levels from colonic administration 
of 600 mg phenytoin mirror 300-mg levels to 4 h. How- 
ever, drug-plasma levels are observed to increase further 
from 4 to 8 h, suggesting that continued dissolution of 
phenytoin in the colon provides continued drug absorp- 
tion (Fig. 2 and Table 1). 
DISCUSSION 
Small intestinal absorption of gabapentin is postulated 
to include a carrier-mediated (neutral amino acid trans- 
port) system (1 1) in parallel with a nonsaturable path- 
way. The presence of amino acid carriers and a leaky 
nonsaturable paracellular pathway in the upper small in- 
testine may contribute to the rapid upper intestinal ab- 
sorption of gabapentin observed when gabapentin was 
administered orally compared with intestinal and colonic 
administration. The absence of amino acid carriers in the 
colon combines with a more restricted paracellular path- 
way to limit colonic absorption of this hydrophilic drug. 
Gabapentin absorption from the colon is further re- 
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FIG. 1. Colonic administration of gabapentin provides substantially lower drug-plasma levels than those from oral and small intestinal 
administration of an equivalent dose. 
stricted by lipid-membrane permeation. Based on a log 
octanol-water partition coefficient of -1.1 (S), colonic 
absorption of this zwitterionic drug should be minimal. 
Increasing the oral dose of gabapentin has been shown to 
result in a decreased fraction of absorbed dose, suggest- 
ing saturable absorption (1 1). Unabsorbed gabapentin 
that might reach the colon from oral overdose should not 
be a toxicity concern because of poor colonic permeation 
coupled with a distribution and excretion profile favor- 
able for drug elimination. 
Membrane permeation of phenytoin is rapid [log oc- 
tanol-water partition coefficient of 2.0 was determined 
in our laboratory; log 2.4 and 2.47 in other laboratories 
(12)], and dissolution rate is the limiting step for phe- 
nytoin absorption from either gastrointestinal region 
(10). It is noteworthy that very low plasma levels (0.5-3 
mg/ml) have been obtained in this canine study com- 
pared with those typically observed from equivalent oral 
dosing in human studies (2,9). This is a result of high 
first-pass clearance of phenytoin in the dog, a factor that 
has contributed to low canine plasma levels with subse- 
quent therapeutic failure in veterinary practice (7). None- 
theless, three- to fourfold differences in phenytoin 
plasma levels 4.5-8 h after administration document con- 
tinued absorption of drug from the colon at the higher 
dose, because rapid clearance dictates that absorption 
will dominate phenytoin plasma-level variability. 
In massive overdose cases for lipophilic AEDs like 







































AUC, area under the drug plasma-versus-time curve; C,, peak drug plasma concentration; ND, not deter- 
mined. 
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FIG. 2. Colonic administration of phenytoin provides equivalent maximum plasma concentrations compared with jejunal administration. 
Small intestinal administration results in an earlier time to peak plasma concentrations sustained by continued absorption as drug 
proceeds down the gastrointestinal tract. Colonic administration of higher doses provides equivalent initial plasma concentration, but 
continued dissolution and absorption in the colon results in continued plasma-level increases. 
phenytoin, continued absorption of undissolved drug in 
the colon of comatose patients may provide the sustained 
toxic plasma levels reported in the literature. Based on 
rotating-basket dissolution studies performed in our 
laboratory (13), total dissolution time for 250 mg phe- 
nytoin powder in aqueous media is 11.5 h. Whereas the 
amount of phenytoin overdose that resulted in measur- 
able blood levels for 12 days was not known (2), 62 
capsules containing 100 mg of phenytoin would require 
12 days for total dissolution. Because hepatic clearance 
of phenytoin is saturable within the normal dose range in 
humans, considerably less phenytoin powder mass would 
be required to sustain plasma levels over the time re- 
ported for massive overdose (2). Massive overdose of 
more hydrophilic AEDs like gabapentin would not be 
anticipated to sustain elevated drug-plasma levels, pro- 
vided elimination half-life is relatively short [5-6 h in 
humans (S)]. Although the high concentration from an 
overdose increases the gradient driving force for absorp- 
tion, membrane permeation rather than dissolution limits 
colonic absorption of hydrophilic drugs. 
Although phenytoin plasma levels are more sensitive 
to variable absorption in a canine model, this study con- 
firms that colonic absorption should not be rate limiting 
to plasma levels, a result that should extend to human 
subjects. Based on phenytoin's slow elimination in hu- 
mans, which is typical of marketed lipophilic AEDs, it 
may be important to purge the bowel in patients who 
have overdosed on poorly water-soluble AEDs like phe- 
nytoin . 
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